🐻 Bitcoin Bear Market ?

Good afternoon! The Washington Post is swinging the axe again, cutting about 30% of its newsroom and laying off more than 300 journalists as financial pressure keeps mounting. The move is one of the biggest rounds of cuts yet under owner Jeff Bezos and comes as the paper struggles with subscriber losses, falling traffic, and years of red ink.

Leadership says the future focus will shift harder toward national politics, while international coverage shrinks and the sports desk is nearly wiped out. The Post Guild is pushing back hard, calling for new ownership and organizing a rally, as one of America’s most storied newsrooms gets dramatically smaller.

Bitcoin $BTC has dropped to levels not seen since October 2024, now down more than 20% this year and nearly 50% from its all-time high. What used to be a reliable buy-the-dip market has turned into a slow grind lower, and analysts say this looks more like a reset than a routine pullback. The bigger issue is not just price action but the lack of clear catalysts to spark a bounce.

Bear Market Signals Are Flashing

On-chain indicators that often mark the start of longer downturns have flipped, while spot demand and institutional flows have both cooled. Bitcoin has also slipped below long-term moving averages that historically hold during bull cycles. Analysts are now watching a potential support zone in the high $50,000s to low $60,000s if the $70,000 area gives way.

Crypto is also trading like a risk asset again, and the broader macro backdrop is not helping. Slowing growth, high equity valuations, geopolitical tensions, and tariff risks are pushing investors toward defense. Even the digital gold narrative is wobbling as precious metals climb while bitcoin lags, showing that tighter liquidity is weighing on speculative trades.

ETF Flows and Corporate Pressure Build

Hopes that US crypto legislation would unlock a fresh wave of institutional demand have faded as negotiations drag on. That caution is showing up in ETF flows, which have slowed noticeably compared with last year’s surge. Analysts say bitcoin needs a real liquidity catalyst, such as easier monetary policy or a strong rebound in ETF inflows, but neither is happening right now.

Last year’s boom in corporate bitcoin treasuries is also becoming a risk. Many companies that bought heavily are sitting on losses, and if prices keep sliding alongside their own shares, some could be forced to sell to shore up balance sheets. That potential supply overhang adds more weight to a market already struggling with weak demand and fading momentum.

Telehealth company Hims & Hers $HIMS is rolling out a far cheaper version of Novo Nordisk’s $NVO Wegovy pill, kicking off what could turn into one of the fiercest pricing battles yet in the red-hot weight-loss drug market. Hims says it will sell a compounded oral GLP-1 for $49 for the first month and $99 per month after, compared with about $199 to start for Novo’s branded version.

Novo did not stay quiet. The drugmaker says it plans to pursue legal and regulatory action, arguing the copy raises patent and safety concerns. Investors reacted fast, with volatility hitting shares of Hims, Novo, and even Eli Lilly $LLY as traders weighed the risk of cheaper alternatives eating into one of pharma’s most profitable categories.

A Cheaper Pill With Bigger Questions

At the center of the dispute is how well the drug actually works. Novo’s pill relies on a patented delivery system that helps the active ingredient survive digestion and be absorbed properly. Hims says its version uses liposomal technology, but has shared limited details so far.

Compounded drugs do not go through the same full FDA clinical trial process as branded medications. Novo argues large-scale compounding of GLP-1 drugs is both risky and unlawful, while Hims says it is expanding access with a more affordable option. Outside experts note that fine-tuning dosing in pill form is complex, and replicating Novo’s absorption technology may not be easy.

This Rivalry Has History

This is not the first clash between the two. During GLP-1 shortages in 2024, Hims and other telehealth firms sold compounded versions of Novo’s injectable weight-loss drugs. Even after supply improved, Hims continued offering what it describes as personalized alternatives, drawing lawsuits and public criticism from Novo.

Regulators have moved slowly, leaving a gray area that telehealth companies have used to meet strong consumer demand. Analysts say the pattern is familiar: big pharma pushes back, regulators deliberate, and lower-cost providers rush in while rules are still being debated.

The GLP-1 Gold Rush Gets Crowded

Novo’s oral Wegovy is the first GLP-1 weight-loss pill, and early demand has been strong, especially among new patients. But competition is heating up quickly. Eli Lilly is expected to launch its own pill later this year, and now Hims is attempting to undercut both rivals on price.

For investors, the bigger issue is pricing power. If compounded versions gain traction, the sky-high margins that fueled the weight-loss drug boom may not look as durable as once thought.

Tomorrow’s calendar is a little lighter on the jobs front after the monthly employment report got pushed back, but there’s still enough data to keep traders busy. We’ll get an early read on how consumers are feeling this month along with fresh numbers on how much Americans leaned on credit cards and loans at the end of last year.

On the earnings side, a mix of global brands and financial heavyweights step up to the mic, including automakers, apparel names, tobacco giants, European banks, healthcare insurers, and car retailers. And outside of markets, the Winter Olympics officially begin with the opening ceremony in Milan and Cortina d’Ampezzo, giving the world a primetime distraction from charts and spreadsheets.

Join our options subreddit ⚡️: https://www.reddit.com/r/optionstrading/

Join our discord community 💠: https://discord.gg/optionality

Check out our latest issues 🎯: 0ptionality.com